Comprehensive Cost-Utility Analysis of Newborn Screening Strategies
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inborn errors of metabolism are a significant cause of morbidity and death among children. Inconsistencies in how individual states arrive at screening strategies, however, lead to marked variations in testing between states. OBJECTIVE: To determine the cost-effectiveness of each component test of a multitest newborn screening program, including screening for phenylketonuria, congenital adrenal hyperplasia, congenital hypothyroidism, biotinidase deficiency, maple syrup urine disease, galactosemia, homocystinuria, and medium-chain acyl-CoA dehydrogenase deficiency. METHODS: A decision model was used, with cohort studies, government reports, secondary analyses, and other sources. Discounted costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios were measured. RESULTS: All except 2 screening tests dominated the "no-test" strategy. The 2 exceptions were screening for congenital adrenal hyperplasia, which cost slightly more than $20,000 per QALY gained, and screening for galactosemia, which cost $94,000 per QALY gained. The screening test with the lowest expected cost was tandem mass spectrometry. The results found in our base-case analysis were stable across variations in nearly all variables. In instances in which changes in risks, sequelae, costs, or utilities did affect our results, the variation from base-case estimates was quite large. CONCLUSIONS: Newborn screening seems to be one of the rare health care interventions that is beneficial to patients and, in many cases, cost saving. Over the long term, funding comprehensive newborn screening programs is likely to save money for society.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Infants ascertained through screening have less severe hyponatremia and shorter hospitalizations (238,242,246,247).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [246]
In the citing paper
“Recent estimates have ranged widely from $20,000 (59) to $250,000 to $300,000 (60) per qualityadjusted life year.”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [59]
In the citing paper
“First-tier screens for CAH employ immunoassays to measure 17OHP in dried blood spots on the same filter paper (”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [59]
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Recommendations of the Panel on Cost-Effectiveness in Health and Medicine
Weinstein, M. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540150055031 · Cited by 2,455
A SIMPLE PHENYLALANINE METHOD FOR DETECTING PHENYLKETONURIA IN LARGE POPULATIONS OF NEWBORN INFANTS
Guthrie, R., & Susi, A. (1963) · Pediatrics · doi:10.1542/peds.32.3.338 · Cited by 2,219
Use of intensive care at the end of life in the United States: An epidemiologic study*
Angus, D. C., Barnato, A. E., Linde-Zwirble, W. T., Weissfeld, L. A., Watson, R. S., Rickert, T., & Rubenfeld, G. D. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000114816.62331.08 · Cited by 1,155
(2001) · PsycEXTRA Dataset · doi:10.1037/e548252006-001 · Cited by 1,018
Willingness to Pay for a Quality-adjusted Life Year: In Search of a Standard
Hirth, R. A., Chernew, M. E., Miller, E., Fendrick, A. M., & Weissert, W. G. (2000) · Medical Decision Making · doi:10.1177/0272989x0002000310 · Cited by 850
Deaths: Preliminary Data for 2001: (566622006-001)
Arias, E., & Smith, B. L. (2003) · PsycEXTRA Dataset · doi:10.1037/e566622006-001 · Cited by 661
Schendel, D., Grosse, S. D., Homsi, G., Chen, H., Dunlap, L. J., & Honeycutt, A. (2004) · Cited by 461
The Influence of Intellectual Disability on Life Expectancy
Bittles, A. H., Petterson, B. A., Sullivan, S. G., Hussain, R., Glasson, E. J., & Montgomery, P. D. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.7.m470 · Cited by 450
Waisbren, S. E. (2003) · JAMA · doi:10.1001/jama.290.19.2564 · Cited by 360
Research works printed but not linked: 3
- Centers for Disease Control and Prevention. Using tandem mass spectrometry for metabolic disease screening among newborns. MMWR Morb Mortal Wkly Rep. 2001;50:1–22. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/rr5003a1.htm. Accessed May 13, 2004
- National Newborn Screening and Genetics Resource Center. Homocystinuria. In: National Newborn Screening Report—2000. Austin, TX: National Newborn Screening and Genetics Resource Center; 2003:1–11. Available at: http://genes-r-us.uthscsa.edu/resources/newborn/00/ch7_complete.pdf. Accessed June 23, 2004
- US Congress, Office of Technology Assessment. Data and methods used in OTA's cost-effectiveness analysis of strategies for newborn screening. In: Healthy Children: Investing in the Future. Washington, DC: US Government Printing Office; 1988:236–241. Publication OTA-H-345. Available at: www.wws.princeton.edu/cgi-bin/byteserv.prl/∼ota/disk2/1988/8819/881919.PDF. Accessed June 3, 2004
Cited by
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Early Childhood Assessment: Why, What, and How
Snow, C. E., & Hemel, S. B. V. (2008) · Cited by 336
PW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
Metadata
- Authors
- Carroll, A. E., & Downs, S. M.
- Affiliations
- Regenstrief Institute (US)
- Venue
- PEDIATRICS
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2006-05-01
- Volume
- 117
- Issue
- Supplement_3
- Pages
- S287-S295
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2147142253
- Cited by
- 165
- References
- 39
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 8 · 2023: 8 · 2022: 9 · 2021: 9 · 2020: 13 · 2019: 13 · 2018: 3 · 2017: 9 · 2016: 6 · 2015: 8 · 2014: 10 · 2013: 10 · 2012: 5
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- PEDIATRICS (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k23dk067879-02)
- National Institute of Diabetes and Digestive and Kidney Diseases (K23 DK67879-01)
- Maternal and Child Health Bureau
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
- Keywords
- newborn screening, cost-effectiveness, inborn errors of metabolism, phenylketonuria, congenital adrenal hyperplasia, congenital hypothyroidism, biotinidase deficiency, maple syrup urine disease, galactosemia, homocystinuria, medium-chain acyl-CoA dehydrogenase deficiency, tandem mass spectrometry, quality-adjusted life years, incremental cost-effectiveness ratio, decision models
- MeSH terms
- Cost-Benefit Analysis, Decision Support Techniques, Humans, Infant, Newborn, Metabolism, Inborn Errors, Mass Spectrometry, United States, Neonatal Screening
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comprehensive Cost-Utility Analysis of Newborn Screening Strategies. https://app.cochat.ai/papers/10.1542/peds.2005-2633h
- The paper
- Carroll, A. E., & Downs, S. M. (2006). Comprehensive Cost-Utility Analysis of Newborn Screening Strategies. PEDIATRICS. https://doi.org/10.1542/peds.2005-2633h
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.